Contrast agent developer Epix Medical reported third-quarter revenues of $3.6 million, up 89% from the $1.9 million booked in the third quarter of 2000. For the period (end-September 30), the Cambridge, MA-based firm had a net loss of $4 million, compared with a net loss of $4.3 million reported in the third quarter of 2001.
During the third quarter, Epix received $1.8 million from a product development contract with Schering, and $1.8 million from a patent licensing and royalty agreement from Bracco Imaging. In the third quarter of 2000, Epix received $1.9 million from the Schering development contract.
By AuntMinnie.com staff writersOctober 19, 2001
Related Reading
Epix, Bracco ink licensing deal, September 25, 2001
Wirth joins Epix Medical board, August 30, 2001
Epix net loss grows in Q2, July 27, 2001
Epix trims net loss, April 27, 2001
Epix, InSightec, Brigham and Women's team up, March 12, 2001
Copyright © 2001 AuntMinnie.com
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
